Durvalumab + Oleclumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle Invasive Bladder Cancer
Conditions
Muscle Invasive Bladder Cancer
Trial Timeline
Feb 20, 2019 → Aug 2, 2021
NCT ID
NCT03773666About Durvalumab + Oleclumab
Durvalumab + Oleclumab is a phase 1 stage product being developed by AstraZeneca for Muscle Invasive Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03773666. Target conditions include Muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04262375 | Phase 2 | Withdrawn |
| NCT04262388 | Phase 2 | Withdrawn |
| NCT03875573 | Phase 2 | Active |
| NCT03773666 | Phase 1 | Completed |
Competing Products
20 competing products in Muscle Invasive Bladder Cancer